Clinical Trial News Archive - February 2019
February 11, 2019
- Sanofi and Regeneron Offer Praluent (alirocumab) at a New Reduced U.S. List Price
- Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
February 15, 2019
February 19, 2019
February 20, 2019
- Immunomedics Announces Publication of Triple-Negative Breast Cancer Data With Sacituzumab Govitecan in the New England Journal of Medicine
- Biohaven Enrolls First Patient In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole
February 21, 2019
February 23, 2019
February 25, 2019
- U.S. FDA Grants Breakthrough Therapy Designation (“BTD”) to Amicus’ AT-GAA in Late Onset Pompe Disease
- Glenmark Pharmaceuticals Announces Results from New Analysis of Pooled Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting
Clinical trial results archive
- 2025
- January, February, March
- 2024
- January, February, March, April, May, June, July, August, September, October, November, December
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.